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Abstract
Fungal ribotoxins that block protein synthesis can be useful warheads in the context of a targeted
immunotoxin. α-Sarcin is a small (17 kDa) fungal ribonuclease produced by Aspergillus giganteus
that functions by catalytically cleaving a single phosphodiester bond in the sarcin–ricin loop of the
large ribosomal subunit, thus making the ribosome unrecognisable to elongation factors and lead-
ing to inhibition of protein synthesis. Peptide mapping using an ex vivo human T cell assay deter-
mined that α-sarcin contained two T cell epitopes; one in the N-terminal 20 amino acids and the
other in the C-terminal 20 amino acids. Various mutations were tested individually within each epi-
tope and then in combination to isolate deimmunised α-sarcin variants that had the desired prop-
erties of silencing T cell epitopes and retention of the ability to inhibit protein synthesis
(equivalent to wild-type, WT α-sarcin). A deimmunised variant (D9T/Q142T) demonstrated a com-
plete lack of T cell activation in in vitro whole protein human T cell assays using peripheral blood
mononuclear cells from donors with diverse HLA allotypes. Generation of an immunotoxin by
fusion of the D9T/Q142T variant to a single-chain Fv targeting Her2 demonstrated potent cell kill-
ing equivalent to a fusion protein comprising the WT α-sarcin. These results represent the ﬁrst fun-
gal ribotoxin to be deimmunised with the potential to construct a new generation of deimmunised
immunotoxin therapeutics.
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Introduction
Immunotoxins are chimeric molecules containing a targeting moi-
ety linked to a toxin (Alewine et al., 2015; Wayne et al., 2014)
and are primarily used as therapeutics to speciﬁcally target cells
for destruction by the toxin while avoiding normal healthy cells.
The targeting portion can be an antibody, antibody fragment or
some other targeting protein (e.g. abdurin, cytokine, peptide,
ligand and hormone) designed to bind to a speciﬁc cell-surface
molecule or receptor. OntakTM is the ﬁrst, and only, immunotoxin
approved by the FDA for the treatment of certain B cell
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leukaemias (Wayne et al., 2014). It comprises an interleukin-2
receptor targeting moiety, in the form of interleukin-2 fused to a
truncated form of diphtheria toxin, which is a very potent inhibi-
tor of protein synthesis.
Many toxin warheads have been investigated for potential devel-
opment as immunotoxin-based therapeutics including: ricin, diph-
theria toxin, pseudomonas exotoxin A, gelonin, bouganin, saponin
and various mutants of each (Alewine et al., 2015; Antignani and
Fitzgerald, 2013; Carreras-Sangrà et al., 2008). A number of these
immunotoxins have been tested in clinical trials, particularly PE38
(a truncated pseudomonas exotoxin A variant), gelonin and ricin
(Borthakur et al., 2013; Hassan et al., 2013, 2014; Kreitman et al.,
2000, 2009; Schnell et al., 2003; Schindler et al., 2011).
Unfortunately, all of these trials have reported the development of
treatment-limiting anti-drug antibodies (ADA), although the fre-
quency of patients developing ADA (varying from a few per cent to
90%) depended upon the disease and their immune competence.
Furthermore, the presence of pre-existing ADA as a result of vaccin-
ation or environmental exposure can also interfere with treatment
(Hu, 1995; Matar et al., 2012; Manning et al., 2015). The immuno-
genicity of toxins that are derived from plants or microbial sources
almost certainly arises as a result of a lack of immunological toler-
ance, i.e. the non-human protein is recognised as foreign by the
patient’s immune system. It is possible to address immunogenicity
that arises as a consequence of the ‘foreignness’ of a protein by
mutating B and/or T cell epitopes. The limitation of targeting B cell
epitopes recognised by the pre-existing ADA (Nagata and Pastan,
2009) is that the ADA response can develop upon repeated treat-
ment with the protein resulting in the recognition of new epitopes
through a process of epitope spreading and this process is driven by
the presence of CD4+ T cell epitopes in the protein sequence. It is
known that CD4+ T cell epitopes are the principle drivers of ADA
responses in vivo (Baker and Carr, 2010). Eliminating T cell epi-
topes will, therefore, prevent the generation of both T cell and B cell
responses, an approach that has recently been applied to PE38
(Mazor et al., 2014).
Ribotoxins constitute a family of cytotoxic secreted fungal
RNases, best represented by α-sarcin (Lacadena et al., 2007). They
cleave a single phosphodiester bond of the larger rRNA, located at
the universally conserved site in the sarcin–ricin loop (SRL).
Cleavage of the SRL results in ribosome inactivation leading to
protein biosynthesis inhibition and cell death (García-Ortega et al.,
2010; Lacadena et al., 2007; Martínez-Ruiz et al., 2001;
Olombrada et al., 2014). Fungal ribotoxins have several advan-
tages in the context of developing a therapeutic immunotoxin,
these include small size, high thermostability, resistance to pro-
teases and their highly efﬁcient ability to inactivate ribosomes
(Goyal and Batra, 2000; Lacadena et al., 2007; Rathore et al.,
1997). They have not, however, been so frequently employed as
bacterial toxins in the development of therapeutic immunotoxins,
and so far only preliminary characterisation has been reported
(Better et al., 1992; Goyal and Batra, 2000; Rathore et al., 1997;
Wawrzynczak et al., 1991). Most recently, a colon cancer-speciﬁc
immunotoxin based on α-sarcin has been described (Carreras-
Sangrà et al., 2008) that exhibited highly speciﬁc antitumour activ-
ity in mice harbouring colon tumour xenografts (Tomé-Amat
et al., 2015b). These results support the potential clinical applica-
tion of ribotoxin-based immunotoxins, and particularly those
based on α-sarcin. Although low immunogenicity has been
reported for certain ribotoxins (Goyal and Batra, 2000; Rathore
and Batra, 1996), given the non-human source of the protein there
is still a signiﬁcant risk of immunogenicity which must be consid-
ered before development as a therapeutic immunotoxin for use in
humans. Thus, it is essential for long-term treatment of patients to
have non-immunogenic toxins.
To this end, we sought to deimmunise α-sarcin using a preclin-
ical ex vivo human T cell assay (EpiScreenTM) (Jones et al., 2004)
to identify linear T cell epitopes present within the α-sarcin
sequence. Overlapping peptides spanning the entire sequence were
tested for the capacity to induce T cell proliferation against a
cohort of community blood donors carefully selected based on
expression of a broad range of major histocompatibility complex
(MHC) class II haplotypes. Using this assay, two T cell epitopes
were identiﬁed within α-sarcin: Epitope 1 (Residues 10–18) and
Epitope 2 (Residues 134–142). Guided mutational design was used
to predict changes that could be made within the identiﬁed T cell
epitopes that eliminated MHC class II binding and therefore
removed the epitopes. Selection of deimmunised α-sarcin variants
was based on retaining equal or better cytotoxicity as wild-type
(WT) α-sarcin in in vitro transcription and translation (IVTT) and
in vitro cellular toxicity assays; as well as deimmunised α-sarcin
being non-immunogenic (compared to WT α-sarcin) when tested as a
whole protein in the ex vivo T cell assay (Holgate et al., 2015). A
deimmunised α-sarcin variant containing the mutations D9T and
Q142T was as potent as WT α-sarcin and demonstrated complete
silencing of the T cell epitopes when tested in the ex vivo T cell assay.
Materials and methods
In Vitro Transcription/Translation assay
IVTT assays were performed using DNA directly in the assay; the
gene encoding WT α-sarcin corresponding to Residues 1–150
(Genbank accession no. BAA02863, amino acids 28–177) and con-
taining a C-terminal stop codon was cloned into the T7 expression
plasmid pET22b (Millipore UK Ltd, Watford, UK) downstream of
the Nde I site. In addition, a null mutant of WT α-sarcin with the
mutation, H137Q (α-sarcin-H137Q) (Lacadena et al., 1999), was
generated as a negative control using PCR-based site directed
mutagenesis. Plasmid DNA was puriﬁed using a Qiaprep Spin
Mini-prep Kit (Qiagen, Manchester, UK). The cell-free IVTT assay
was performed with a TnT® T7 Coupled Reticulocyte Lysate
System (Promega, Southampton, UK) according to the manufac-
turer’s instructions, with some modiﬁcations. pET22b plasmids
containing either WT α-sarcin or α-sarcin-H137Q were tested at
concentrations ranging from 400 to 6.25 ng per 12.5 µl reaction.
The test DNA was combined with the IVTT reaction mix supple-
mented with 0.1% Triton X-100, 0.2 mM MgCl2 and 12.2 mM
KCl and incubated at 22°C for 45 min. Following a subsequent
cooling step at 4°C for 5 min, 250 ng of T7 luciferase plasmid pro-
vided with the TnT® T7 Coupled Reticulocyte Lysate System were
added and the reactions incubated at 24°C for a further 90 min.
The reactions were stopped by placing the samples on ice and luci-
ferase activity was measured using Steady Glo reagent (Promega,
Southampton, UK), according to the manufacturer’s instructions.
Luminescence was measured in a FluoStar Optima plate reader
(BMG Labtech, Ortenberg, Germany).
Protein expression
Trastuzumab (anti-Her2) scFv-sarcin fusions were cloned into
pET22b downstream of a modiﬁed outer membrane protein A
leader peptide, which has been shown to have improved processing











and export compared to the original sequence (Lacadena et al.,
1994), and upstream of a 6× His tag. Initially, a furin cleavage site
(RSKR) (Hosaka et al., 1991) was engineered between the scFv and
the α-sarcin sequence to enable cleavage and release of mature toxin
following internalisation and transport to the Golgi in target cells
(Goyal and Batra, 2000); later constructs contained a G4S linker.
Two null mutants of α-sarcin were also generated in the same con-
ﬁguration to serve as negative controls, namely α-sarcin-H137Q and
α-sarcin-E96Q (Lacadena et al., 1999). In order to express the α-sar-
cin variants (including null-mutants H137Q and E96Q), an
Escherichia coli BL21-DE3 strain Shufﬂe™ T7 Express (NEB,
Hitchin, UK) derivative overexpressing the chaperonins GroEL/S
was used. Bacteria were transformed with expression plasmids and
plated out. Single colonies were picked and grown in 2YT broth
overnight at 37°C. The following day, the overnight culture was
diluted 1:20 in 2YT broth and bacterial growth at 37°C was moni-
tored by OD600 measurement. Protein expression was induced at
OD600nm = 1.0 by adding IPTG to give a ﬁnal concentration of
1 mM and the culture was then grown at 20°C overnight before cells
were harvested by centrifugation and frozen overnight at −80°C.
Cell pellets were resuspended in B-PER (ThermoFisher, Waltham,
MA) containing DNase I (Roche Diagnostics Ltd, Burgess Hill, UK)
and protease inhibitors (Roche Diagnostics Ltd, Burgess Hill, UK).
The insoluble protein was removed by centrifugation at 26 000 g
for 30 min. Soluble protein was diluted 2-fold in 40mM Tris-HCl
pH 7.5, 300 mM NaCl, 80 mM imidazole and clariﬁed by centrifu-
gation before addition of 1 ml Ni-NTA-agarose (Qiagen,
Manchester, UK) pre-equilibrated with 20mM Tris-HCl pH 7.5,
300 mM NaCl and 40mM imidazole (binding buffer). After incuba-
tion with rotation overnight at 4°C, unbound protein was removed
by centrifugation of the Ni-NTA-agarose followed by a 10-column
volumes wash with binding buffer. A stepwise wash/elution was
then performed starting with a 10-column volumes wash with
20 mM Tris-HCl pH 7.5, 300mM NaCl, 100mM imidazole (wash
buffer) followed by elution with 20mM Tris-HCl pH 7.5, 300mM
NaCl, 400mM imidazole (elution buffer). One millilitre elution frac-
tions were collected and analysed by SDS-PAGE. Fractions containing
the protein of interest were pooled, buffer exchanged into PBS pH 7.4
and soluble protein quantiﬁed by OD280nm (Ec(0.1%) = 1.57).
Cellular cytotoxicity assays
For anti-Her2 scFv-sarcin fusions, the Her2 + human breast cancer
cell line BT-474 (LGC Standards, Teddington, UK) was used as the
target. Brieﬂy, cells in the log phase of growth were harvested,
diluted to 4 × 104 cells/ml in normal growth media DMEM/F-12
(Life Technologies, Paisley, UK) and 100 μl dispensed into each well
of a 96-well white-walled tissue culture plate (Greiner Bio-One,
Stonehouse, UK). Outer wells contained growth media only in order
to avoid edge effects. Cells were incubated overnight in a humidiﬁed
cell culture incubator (37°C, 5% CO2). A dilution plate was pre-
pared containing a 3-fold dilution (from either 702–0.04 or 234–
0.01 nM) in normal growth media across the plate of each test sam-
ple, and 50 µl of each dilution series was transferred directly onto
the BT-474 cells, from which 50 µl of media had been removed,
before returning the cells to the incubator and incubations were car-
ried out for 7 days. After incubation, the plate was equilibrated at
room temperature for 10min and then developed by the addition of
100 µl of Cell TiterGlo reagent (Promega, Southampton, UK) to
each well prior to reading in a FluoStar Optima plate reader (BMG
Labtech, Aylesbury, UK).
Ex vivo T cell assay donor selection
Peripheral blood mononuclear cells (PBMCs) were isolated from
healthy community donor buffy coats (from blood drawn within
24 h) with appropriate consent and obtained from the UK National
Blood Transfusion Service (Addenbrooke’s Hospital, Cambridge, UK).
PBMCs were isolated from buffy coats by Lymphoprep (Axis-shield,
Dundee, UK) density centrifugation and CD8+ T cells were depleted
using CD8+ RosetteSep™ (StemCell Technologies Inc, London, UK).
Human leukocyte antigen-D related (HLA-DR) haplotypes were deter-
mined using an HLA sequence speciﬁc primer- PCR based tissue-typing
kit (Biotest, Solihull, UK). PBMCs were frozen and stored in liquid
nitrogen until required.
Ex vivo human T cell assays
T cell epitope mapping
Fifteen-mer peptides overlapping by 12 amino acids spanning the
entire WT α-sarcin sequence, plus peptides spanning the null muta-
tions E96Q and H137Q, were synthesised on a 1–3 mg scale with
free N-terminal amine and C-terminal carboxylic acid (Mimotopes,
Clayton, Australia). Peptides were dissolved in DMSO to a concen-
tration of 10 mM and peptide culture stocks prepared by diluting
into AIM-V® culture medium (Gibco, Paisley, UK) to a ﬁnal concen-
tration of 5 µM. Peptide assays were performed as previously
described (Jones et al., 2004) using a cohort of 52 donor PBMC.
Brieﬂy, for each peptide and each donor, sextuplicate cultures were
established in a ﬂat bottomed 96-well plate. For a positive control,
phytohaemagglutinin (PHA, Sigma, Poole, UK) was used at a ﬁnal
concentration of 2.5 µg/ml and also tested in sextuplicate. Cultures
were incubated for a total of 6 days before adding 0.75 µCi 3[H]-
thymidine (Perkin Elmer®, Beaconsﬁeld, UK) to each well. Cultures
were incubated for a further 18 h before harvesting onto ﬁlter mats
using a TomTec Mach III cell harvester. Counts per minute (CPM)
for each well were determined by Meltilex™ (Perkin Elmer®,
Beaconsﬁeld, UK) scintillation counting on a Microplate Beta
Counter (Perkin Elmer®, Beaconsﬁeld, UK in paralux, low back-
ground counting mode).
Positive responses were deﬁned by a stimulation index
(SI = mean cpm of test wells /mean cpm medium control wells)
equal to or greater than 1.9 (SI ≥ 1.90) where the average cpm in
the test wells was signiﬁcantly (P < 0.05) different to the average
cpm of the medium control wells using an unpaired two sample
Student’s t-test. T cell epitopes were identiﬁed by calculating the
average frequency of positive responses (deﬁned above) to all peptides
in the study plus standard deviation to give a background response
rate. Any peptide that induced proliferative responses above the back-
ground response rate was considered to contain a T cell epitope.
Whole protein assays
T cell assays were performed by comparing deimmunised α-sarcin
variants on the null-mutant α-sarcin-E96Q (this mutation was not
associated with a T cell epitope, Fig. 1) background to avoid the
inﬂuence of the cytotoxic effects of the protein on T cell activation.
An in vitro co-culture of autologous CD4+ T cells with matured
dendritic cells (DC:T cell) assay format as previously described
(Holgate et al., 2015), including keyhole limpet haemocyanin (KLH)
and humanised anti-A33 antibody controls, was used with a cohort
of 20 donor PBMC to test the deimmunised α-sarcin variants at a
ﬁnal assay concentration of 50 µg/ml. To conﬁrm that the deimmu-
nised α-sarcin variants were not detrimental to DC viability, the DC
harvested at Day 8, prior to irradiation and co-culture with











autologous T cells, were counted and viability assessed using trypan
blue (Sigma, Poole, UK) dye exclusion. Following a 7-day co-culture
with autologous T cells, the cultures were pulsed with 1.0 µCi 3H-
thymidine (Perkin Elmer, Buckinghamshire, UK) in 50 μl AIM-V®
medium and incubated for a further 6 h before harvesting and scin-
tillation counting as above. Positive responses were deﬁned as above
where SI ≥ 1.90 (P < 0.05).
In silico analysis of T cell epitopes
The sequences of peptides that were positive in the proliferation
assay were analysed primarily using predictive iTope™ software
(Perry et al., 2008) for HLA-DR binding. This software predicts
favourable interactions between amino acid side chains of the pep-
tide and speciﬁc binding pockets within the MHC class II binding
groove. Analysis of the peptide sequences using iTope™ was per-
formed with overlapping 9mers spanning the peptides which were
tested against each of 34 MHC class II alleles. 9mers that pro-
duced a high mean binding score were identiﬁed and from the
T cell proliferation data 9mers which were considered critical to
T cell responses (core 9mers) were highlighted. Where no such
core 9mer could be identiﬁed for peptides that were positive in the
proliferation assay, further analysis was undertaken for potential
binding to HLA-DQ alleles based upon HLA-DQ binding motifs
(Ettinger and Kwok, 1998; Godkin et al., 1997; Johansen et al.,
1996; Kwok et al., 1996; Sidney et al., 1994, 2002, 2010; van de
Wal et al., 1997; Vartdal et al., 1996). Where motifs were identi-
ﬁed, potential 9mers associated with the T cell epitopes were
highlighted.
Results
T cell epitope mapping
A cohort of 52 donors was selected to best represent the number
and frequency of HLA-DR allotypes expressed in the world popula-
tion (Supplementary Fig. S1) and used to test a total of 55 overlap-
ping peptides, which were derived from the WT α-sarcin and
null-mutant (both E96Q and H137Q) amino acid sequences.
Peptides were tested in the T cell assay for the presence of CD4+ T
cell epitopes and positive T cell responses were deﬁned by donors
that produced a signiﬁcant (P < 0.05) proliferation response with a
SI ≥1.90 to any given peptide. T cell epitopes were identiﬁed by cal-
culating the average frequency of the positive responses to all pep-
tides in the study plus standard deviation (termed ‘background
response threshold’). This was calculated to be 6.6% and equates to
peptides inducing T cell proliferation (SI ≥ 1.90, P < 0.05) in >3
donors. All donors produced a positive T cell response against the
positive control PHA in the proliferation assay, indicating that cells
in the ex vivo cultures were functional (data not shown).
Figure 1 summarises the peptide T cell epitope map obtained
from the α-sarcin sequence. Two regions contained T cell epitopes
located at the N- and the C-termini of the protein. The C-terminal
T cell epitope (Epitope 2) elicited slightly more frequent T cell pro-
liferation and was considered to be more potent than the N-
terminal T cell epitope (Epitope 1). For both Epitopes 1 and 2,
two overlapping peptides induced proliferation responses in four
or more donors and in most instances the same donors responded
to both peptides. Since the core MHC class II binding 9mer will be
located in at least two overlapping peptides, this result conﬁrmed
the presence of T cell epitopes in these regions. The mean magni-
tude of the T cell proliferation response was low for both T cell
epitopes, ranging between SI 2.06 and 2.55 (Table I). Analysis of
the responding donors to the N-terminal peptides containing
Epitope 1 (Peptides 2 and 3) showed that there were four identical
positively responding donors strongly suggesting the presence of a
single T cell epitope. At least two of these donors also responded
to a peptide (Peptide 4) that was not identiﬁed as containing a
T cell epitope (the frequency of positive responses was below the
6.66% background response threshold). Based on these prolifer-
ation assay data, the core MHC class II binding 9mer was
Fig. 1 CD4+ T cell epitope map of the (A) α-sarcin toxin, (B) null-mutant E96Q
and (C) null-mutant H137Q sequences. Peptides containing T cell epitopes
are shown as coloured bars below the sequences. The frequency of donors
responding (SI ≥1.90, P < 0.05) is given in each bar together with the identi-
ﬁer for the responding donors. The core 9mer sequences of each epitope are
highlighted in red and the null-mutant residues are boxed green.
Table I. Summary of magnitude (mean SI and range) and frequency (% donor response) of positive T cell proliferation responses against
peptides containing T cell epitopes
Peptide no. Sequence Frequency (%) SI range SI mean
2 WTCLNDQKNPKTNKY 9.6 1.95–2.46 2.14
3 LNDQKNPKTNKYETK 9.6 1.91–2.52 2.15
44 VFCGIIAHTKENQGE 7.7 1.90–2.39 2.06
45 GIIAHTKENQGELKL 11.5 1.93–2.62 2.14
53 VFCGIIAQTKENQGE 7.7 1.93–2.58 2.24
54 GIIAQTKENQGELKL 9.6 1.95–5.67 2.97
The position of the p1 anchor in the potential core 9mer is shown in red.











determined to comprise QKNPKTNKY. Assessment of this
sequence using iTope™ in silico MHC class II binding analysis for
binding against 34 HLA-DR alleles showed that this core 9mer
did not bind to any of the HLA-DR alleles (data not shown).
Further analysis of the core 9mer sequence revealed that it dis-
played motifs similar to those in HLA-DQ-restricted T cell epi-
topes (Ettinger and Kwok, 1998; Godkin et al., 1997; Johansen
et al., 1996; Kwok et al., 1996; Sidney et al., 1994, 2002, 2010;
Vartdal et al., 1996; van de Wal et al., 1997), this fact coupled
with the negative result from the in silico HLA-DR binding ana-
lysis suggested that the T cell epitope was HLA-DQ restricted. The
most likely reason Peptide 4 failed to elicit T cell proliferation
responses above the background response threshold (in spite of
containing the same core 9mer) is because residues lying outside
the core 9mer can also play a signiﬁcant role in the development
of a T cell response (Arnold et al., 2002; Godkin et al., 2001;
Knapp et al., 2009; Lovitch et al., 2006; Zavala-Ruiz et al., 2004).
The null mutation α-sarcin-H137Q was located within Epitope 2
and this mutation only had a modest effect on T cell proliferation
compared to the equivalent WT α-sarcin peptide. The same four
donors responded positively to both WT Peptide 44 and the null-
mutant equivalent Peptide 53, while six and ﬁve donors (with three
in common) responded positively to both WT Peptide 45 and null-
mutant Peptide 54, respectively. This is strongly suggestive of a com-
mon T cell epitope that is shared between the WT and null-mutant
α-sarcin-H137Q sequences. In silico analysis of the peptides span-
ning Epitope 2 (Peptides 44 and 45 for WT α-sarcin, and Peptides
53 and 54 for the null mutation α-sarcin-H137Q) identiﬁed an
HLA-DR restricted binding peptide with the putative core 9mer
IIAHTKENQ which bound to 20 out of a total of 34 MHC class II
alleles tested by iTope™. A total of 12 alleles bound this 9mer with
high afﬁnity and with an average positive binding score of 0.6260
(on a scale of 0–1, a positive score is deﬁned as >0.55). The null-
mutant peptide IIAQTKENQ was predicted to bind to a total of 19
MHC class II alleles (in common with those that bound the WT
sequence) and 12 alleles with high afﬁnity (average binding score of
0.6196). Hence, the null-mutant α-sarcin-H137Q was predicted to
generate a slightly weaker variant of Epitope 2—in agreement with
the T cell epitope mapping data.
The null mutation α-sarcin-E96Q was not associated with a
T cell epitope and no donors responded either to peptides containing
this mutation or to the equivalent WT α-sarcin peptides. All deim-
munised α-sarcin variants were, therefore, generated on the α-sarcin-
E96Q background for subsequent testing as whole proteins in the
ex vivo DC:T cell assay; however, the H137Q null mutant was used
as negative control in the IVTT assay during the identiﬁcation of
active mutations in the T cell epitopes (both H137Q and E96Q
mutants were equally inactive in the IVTT assay, data not shown).
Epitope mutations
Based on iTope™ analysis of Peptides 44 and 45 and HLA-DQ
motif analysis of Peptides 2 and 3, amino acid substitutions within
the identiﬁed T cell epitopes were designed to reduce the propensity
for the peptides to bind to MHC class II. Substitutions were targeted
to key anchor residues of the identiﬁed core 9mer (at Positions 1, 4,
6, 7 and 9) (Hill et al., 1994; Jardetzky et al., 1990); hence, for
Epitope 1, mutations were targeted to Q10 (p1), P13 (p4), T15 (p6),
N16 (p7) and Y18 (p9) and for Epitope 2, mutations were targeted
to I134 (p1), K139 (p6), E140 (p7) and Q142 (p9) (changes to p4
were not predicted to signiﬁcantly affect MHC class II binding).
Since the formation of T cell epitopes can be strongly inﬂuenced by
residues adjacent to the core 9mer (e.g. p-1 and p10) (Arnold et al.,
2002; Godkin et al., 2001; Lovitch et al., 2006; Knapp et al., 2009;
Zavala-Ruiz et al., 2004), additional substitutions at Epitope 1 p-1,
replacing a charged side-chain with a non-charged group, were also
tested. Initially, 15 Epitope 1 and 14 Epitope 2 mutations were
tested for activity individually in the IVTT assay and compared to
WT α-sarcin and null-mutant α-sarcin-H137Q (Table II). The
majority of mutations retained activity within 2-fold of WT α-sarcin,
except I134A where a reduction in activity of 10× was observed. In
a number of cases activity was signiﬁcantly improved (Table II). The
ﬁve most active Epitope 1 mutations were combined with the four
most active Epitope 2 mutations into 20 double mutants and a fur-
ther 4 mutants were constructed that contained a single Epitope 1
mutation and two Epitope 2 mutations and again tested in the IVTT
assay (Table III). As before, most mutants retained activity within 2-
fold of WT α-sarcin, with only two (N16K/Q142N and Y18K/
Q142N) giving activity values outside this range.
Table II. Calculated relative IC50 values for single epitope variants





WT – 1.00 H137Q – >100
D9A Epitope 1 1.25 I134A Epitope 2 >10
D9T Epitope 1 0.92 K139D Epitope 2 1.27
Q10K Epitope 1 0.87 K139E Epitope 2 0.88
Q10R Epitope 1 1.23 K139G Epitope 2 1.63
Q10A Epitope 1 0.53 K139Q Epitope 2 0.73
P13I Epitope 1 0.88 K139H Epitope 2 0.71
T15G Epitope 1 0.62 K139N Epitope 2 2.85
T15Q Epitope 1 1.11 E140D Epitope 2 0.65
T15H Epitope 1 0.95 Q142D Epitope 2 1.54
N16R Epitope 1 0.86 Q142N Epitope 2 0.96
N16K Epitope 1 0.89 Q142T Epitope 2 0.66
N16A Epitope 1 0.54 Q142E Epitope 2 1.04
Y18H Epitope 1 0.86 Q142R Epitope 2 0.91
Y18K Epitope 1 0.67 Q142G Epitope 2 0.53
Y18R Epitope 1 0.82 – – –
Values were calculated by dividing the IC50 of the single epitope variant
by that of WT α-sarcin assayed on the same plate.
Table III. Calculated relative IC50 values for double epitope
variants (epitopes 1 + 2)
Mutation Relative IC50 Mutation Relative IC50
WT 1.00 H137Q >100
Q10K K139D 1.16 Y18R K139D 1.05
Q10K K139E 0.98 Y18R K139E 1.37
Q10K Q142N 1.09 Y18R Q142N 1.24
N16R K139D 1.01 Q10K Q142T 0.89
N16R K139E 1.08 N16R Q142T 1.28
N16R Q142N 1.11 N16K Q142T 1.27
N16K K139D 1.62 Y18K Q142T 1.98
N16K K139E 1.79 Y18R Q142T 1.25
N16K Q142N 2.63 Q10K K139D Q142T 0.32
Y18K K139D 1.36 Q10K K139E Q142T 0.22
Y18K K139E 1.49 N16R K139D Q142T 0.27
Y18K Q142N 3.52 N16R K139E Q142T 0.22
Values were calculated by dividing the IC50 of the double epitope variant
by that of WT α-sarcin assayed on the same plate.











WT α-sarcin and null-mutant H137Q were fused to an anti-
Her2 scFv separated by a linker containing a furin cleavage site,
with the sequence RSKR, which was expected to enhance activity
by promoting release of the toxin from the fusion protein in endo-
somes. The scFv fusion proteins were expressed in E. coli and
puriﬁed to homogeneity by nickel chelate chromatography and
tested for binding to Her2 positive BT-474 cells in comparison to
trastuzumab alone and WT α-sarcin alone in order to conﬁrm that
fusion to trastuzumab conferred speciﬁc binding to BT-474 cells
(Supplementary Fig. S2A). Cytotoxicity assays also conﬁrmed that
fusion of WT α-sarcin to trastuzumab gave a 2 log enhancement in
cell killing compared to α-sarcin alone (Supplementary Fig. S2B
and Supplementary Table SI) thus enhancing the natural ability of
α-sarcin to penetrate and kill tumour cells (Lacadena et al., 2007).
Therefore, the best-performing triple mutant in the IVTT assay
(N16R/K139E/Q142T) together with a triple mutant containing
an alternative Epitope 1 mutation that retained good activity
(Q10K/K139E/Q142T) and the most active double mutant
(Q10K/Q142T) were also fused to an anti-Her2 scFv separated by
a furin linker, expressed, puriﬁed and tested in a cell cytotoxicity
assay on BT-474 cells in comparison to the scFv fusion to WT α-
sarcin (Fig. 2A and Supplementary Table SI). When fused to the
anti-Her2 scFv, all three α-sarcin variants displayed at least a 5-
fold reduction in activity compared to WT α-sarcin, both in terms
of potency and maximum cell killing (Fig. 2A). As a result, var-
iants containing each mutation individually were expressed as
anti-Her2 scFv fusion proteins containing the furin cleavage site
and tested for cytotoxicity on BT-474 cells to identify which
mutation was causing the loss of activity (Fig. 2B and
Supplementary Table SI). Fusion proteins containing Q10K or
N16R or K139E were found to have signiﬁcantly reduced activity
compared to WT α-sarcin, with N16R showing the greatest drop
in activity. In contrast, the activity of Q142T was comparable to
WT α-sarcin (within 2-fold). Since Q142T alone was predicted to
effectively reduce MHC class II binding by the C-terminal Epitope
2, a further series of six deimmunised variants was constructed
based upon Q142T containing additional changes within the N-
terminal Epitope 1 (D9T, Q10A, P13I, T15G, Y18K and Y18R)
that had previously been shown to retain good activity in the
IVTT assay (Table II). These double mutant variants were fused to
anti-Her2 scFv via a furin linker and tested for activity on BT-474
cells (Fig. 2C and Supplementary Table SI). From this set of deim-
munised variants, the best activity was shown by P13I/Q142T
with Q10A/Q142T, D9T/Q142T and T15G/Q142T having similar
but slightly lower activity; however, the potency and maximum
cell killing was again reduced compared to WT α-sarcin.
Deimmunised variants containing mutations at Y18 in combin-
ation with Q142T showed greatly reduced activity such that an
IC50 value could not be calculated, although all variants were
more active than the null-mutant H137Q (Fig. 2D and
Supplementary Table SI).
The effect of the furin linker on potency was investigated by
expressing and purifying anti-Her2 scFv fusion constructs linked to
WT α-sarcin either by a furin linker or a non-cleavable G4S linker,
plus deimmunised variants D9T/Q142T and P13I/Q142T linked by
a G4S linker. Constructs were again tested for cell killing on BT-474
Fig. 2 Activity of variant α-sarcin anti-Her2 scFv fusion proteins (containing a furin linker) on Her2 positive BT-474 cells. Serial dilutions of each protein were per-
formed before combining with BT-474 cells. Following incubation at 37 °C 5% CO2 for 7 days, cell viability was assessed in a CellTiter-Glo luminescent cell viabil-
ity assay. (A) Lead variants, (B) lead variant single mutations, (C) Q142T combined with alternative Epitope 1 mutations and (D) activity of null-mutant (NM)
H137Q. Note: for clarity, in panels (A), (B) and (C) error bars are only shown for WT α-sarcin curve.











cells (Fig. 3). Surprisingly, it was found that the presence of the furin
linker in the WT α-sarcin constructs only had a modest beneﬁcial
effect on potency with a 2-fold improvement in toxicity compared
to the G4S linker construct (Fig. 3A and Supplementary Table S1).
Furthermore, the deimmunised variants containing the G4S linker
possessed equivalent toxicity (within 2-fold) to the WT α-sarcin
fusion also containing the G4S linker (Fig. 3B and Supplementary
Table SI). Hence, the toxicity of the deimmunised variants with a
G4S linker was improved compared to those containing a furin
linker, both in terms of potency and maximum cell killing. Based
upon these results, deimmunised variants D9T/Q142T and P13I/
Q142T with the G4S linker were selected as lead candidates and
tested in the whole protein ex vivo DC:T cell assay.
Whole protein T cell assays
The lead deimmunised α-sarcin variants plus the WT protein were
constructed and expressed containing the null mutation E96Q
(Lacadena et al., 1999) that had previously been shown in the pep-
tide mapping assay not to affect T cell responses and not to be asso-
ciated with a T cell epitope. Mutant proteins were expressed and
puriﬁed to homogeneity as described for the active deimmunised α-
sarcin variants. The variants, when used at the concentrations
required for the T cell assay, still retained some residual toxicity;
therefore, the preferred ex vivo T cell assay format comprised of
loading monocyte derived DC with antigen during in vitro matur-
ation. Antigen was endocytosed during this antigen loading step
before any remaining excess was washed from the cultures. The
endocytosed antigen was processed intracellularly by the DC (during
the ﬁnal in vitro maturation step) and then autologous CD4+ T cells
were co-cultured with the DC. This DC:T cell assay format ensured
that subsequent proliferation of T cells was not inﬂuenced by the
residual toxicity of the deimmunised null-mutant α-sarcin-E96Q var-
iants. To conﬁrm that the residual toxicity did not adversely affect
DC during antigen loading/processing, the viability of DC from 10
donors was tested by trypan blue dye exclusion (8 days post-antigen
loading). All cultures (including deimmunised null-mutant α-sarcin-
E96Q variants, control antigens and media alone) were found to
have viabilities in the range of 92–95%. T cell proliferation was
induced against the assay controls KLH and humanised anti-A33
antibody (SI ≥ 1.90, P < 0.05) in 50% and 20% of the donor
cohort, respectively. Deimmunised variant P13I/Q142T and WT α-
sarcin induced positive T cell proliferation in 10% and 20% of the
donor cohort, respectively, and no T cell proliferation responses
were detected against deimmunised variant D9T/Q142T (Fig. 4).
Discussion
Development of therapeutic immunotoxins that contain bacterial
or plant toxins as the cell killing moiety has been hampered by
undesirable immunogenicity. Such proteins, by their very nature,
are immunogenic and induce immunity in humans, even after a sin-
gle administration of the protein (Borthakur et al., 2013; Hassan
et al., 2013, 2014; Kreitman et al., 2000, 2009; Schnell et al.,
2003; Schindler et al., 2011). Deimmunisation through elimination
of both B cell and/or T cell epitopes has been utilised in order to
address the issue of immunogenicity and early progress has been
made with a deimmunised version of PE38 (Mazor et al., 2014;
Nagata and Pastan, 2009). New non-immunogenic toxin warheads
need to be developed and tested in order to provide a new gener-
ation of targeted immunotoxins for the treatment of malignancies.
α-Sarcin is a good candidate toxin warhead since it has been
demonstrated to have potent anti-tumour activity both in vitro and
in animal models of colorectal cancer (Carreras-Sangrà et al.,
2012; Tomé-Amat et al., 2015a). In order to improve therapeutic
utility, we sought to deimmunise α-sarcin by identifying T cell epi-
topes within the protein and then removing them by mutagenesis.
Two T cell epitopes were identiﬁed in α-sarcin with core 9mer
MHC class II binding sequences predicted to comprise amino acids
10–18 and 134–142. The T cell responses to peptides spanning
these regions were weak, suggesting that the healthy donors had
no prior exposure to α-sarcin (although phenotypic analysis of the
proliferating T cells would be required to conﬁrm this) and that α-
sarcin itself is not a potent immunogen. This result is consistent
with observations on the closely related fungal ribotoxin, restricto-
cin (Rathore and Batra, 1996).
Epitope 1 is located in a region within the N-terminal β-hairpin
loop (Pérez-Cañadillas et al., 2000) (amino acids 7–22) that is
involved in the cytotoxicity but not RNase activity of α-sarcin (53,
54 and 55). Since the deletion of this sequence leads to conform-
ational changes within the structure, resulting in a modiﬁcation of
α-sarcin activity (García-Mayoral et al., 2004), it might be
expected that mutations within Epitope 1 may affect the overall
conformation of α-sarcin and could adversely affect activity. In
vitro testing of individual Epitope 1 mutations at positions D9,
Fig. 3 Activity of variant α-sarcin anti-Her2 scFv fusion proteins on Her2 positive BT-474 cells. Serial dilutions of each protein were performed before combining with
BT-474 cells. Following incubation at 37 °C 5% CO2 for 7 days, cell viability was assessed in a CellTiter-Glo luminescent cell viability assay. (A) WT α-sarcin with either
a furin or G4S linker, (B) Epitope 1 mutations D9T and P13I in combination with Q142T containing a G4S linker in comparison to WT α-sarcin with a G4S linker.











Q10, P13, T15, N16 and Y18 that were predicted to remove this
T cell epitope, did not have any signiﬁcant effect on the overall
activity of α-sarcin in the IVTT assay. None of these mutations,
therefore, appeared to have any detrimental effect on the
N-terminal β-hairpin and, by extension, the conformation of the
deimmunised variant α-sarcin proteins. Epitope 2 lies at the end of
the α-sarcin β6 sheet through to the end of loop 5 (Pérez-
Cañadillas et al., 2000). Loop 5 makes numerous contacts with
other parts of the structure via hydrophobic interactions, hydrogen
bonds and salt bridges, in particular E140 has unusual backbone
torsional angles. Loop 5 also makes contacts with the N-terminal
β-hairpin loop principally between E140 and K11, K139 and D9,
K139 and Y18, and H137 + E140 and N8 (Pérez-Cañadillas et al.,
2000); therefore, there is a close structural association between
Epitopes 1 and 2. H137 is also part of the catalytic triad (H50,
E96 and H137) that is essential for α-sarcin activity (Lacadena
et al., 1999) and, therefore, as with Epitope 1, it was possible that
mutations within Epitope 2 could adversely affect the overall con-
formation of α-sarcin and negatively affect α-sarcin activity.
Despite these complex interactions, individual mutations at posi-
tions K139, E140 and Q142 only had a modest effect on activity
whereas the mutation I134A, which lies outside the loop and
within the β6 sheet, resulted in markedly reduced activity, presum-
ably by affecting the structure of the β6 sheet. Due to its key role in
the stabilisation of the loop 5 structure, only one conserved muta-
tion at E140 was tested (E140D) in order to retain the salt bridge
with K11, and this mutation retained activity. Surprisingly, the
activity of mutants carrying Epitope 1 mutations D9T and D9A
was not signiﬁcantly affected despite removing the possibility of a
salt bridge with K139 within Epitope 2.
Combining the ﬁve most active Epitope 1 mutations with the
four most active Epitope 2 mutations into double and triple mutant
combinations resulted in a set of deimmunised variants that retained
activity in the IVTT assay within 2-fold of WT α-sarcin (except
N16K/Q142N and Y18K/Q142N). In particular, the triple mutant
N16R/K139E/Q142T appeared to be highly active, again demon-
strating that, despite these two epitopes being so closely associated
and in regions important for activity, there appeared to be a signiﬁ-
cant sequence plasticity allowing retention of ribosome toxicity even
when changing a positively charged residue to a negatively charged
one. However, the IVTT assay only measures ribosome toxicity,
whereas membrane binding and translocation, are necessary for full
α-sarcin cytotoxicity. Mutational analysis of the lysine rich region
(110–114) has demonstrated its interaction with phospholipids and
loop 2 (Residues 53–93) is involved in membrane penetration
(Castaño-Rodríguez et al., 2015), while the Region 116–139 has
also been proposed to be involved in membrane interaction
(Mancheño et al., 1995, 1998), with R121 speciﬁcally interacting
with phospholipids (Masip et al., 2001). The N-terminal β-hairpin
loop, and K11 in particular, has also been shown to affect mem-
brane translocation (García-Ortega et al., 2001, 2002). Therefore,
mutations within both Epitopes 1 and 2 have the potential to affect
membrane translocation.
Two triple mutants (Q10K/K139E/Q142T and N16R/K139E/
Q142T) and one double mutant (Q10K/Q142T) were fused to an
anti-Her2 scFv via a furin linker, expressed, puriﬁed and tested for
cytotoxicity on Her2+ BT-474 cells. In contrast to the IVTT assay,
the Her2 targeted toxin variants containing the furin cleavage site
were signiﬁcantly less efﬁcient at killing BT-474 cells than the Her2
scFv fusion with WT α-sarcin. Subsequent experiments showed that,
with the exception of Q142T, a range of single and double mutants
previously shown to have activity close to WT α-sarcin in the IVTT
assay were, to varying degrees, less active when fused to the anti-
Her2 targeting domain via the furin linker. The reduction in activity
had two components: a reduction in potency and a reduction in
maximum cell killing. These data suggested several possibilities,
including: (i) the furin linker as constructed in the context of this
particular fusion protein adversely affected membrane translocation,
(ii) the furin linker was not efﬁciently cleaving, as expected; or (iii)
the Her2 target and internalisation pathway inﬂuenced the
Fig. 4 Ex vivo DC:T cell assay in which CD4+ T cell proliferation responses to deimmunised α-sarcin variants and WT α-sarcin were measured. CD4+ T cells were
incubated with autologous mature DC loaded with the samples and assessed for proliferation after 7 days’ incubation. T cell responses with an SI≥1.90 (indi-
cated by red dotted line) that were signiﬁcant (P <0.05) using an unpaired, two sample Student’s t-test were considered positive.











trafﬁcking, processing and escape of the fusion constructs—or all of
the above could be involved.
Subsequent comparison of WT α-sarcin linked to anti-Her2 scFv
either by a furin linker or a G4S linker showed that the cytotoxic
activities on BT-474 cells of these two fusion proteins were very
similar (within 2-fold) with the furin linker construct being slightly
more potent. Comparison of anti-Her2 fusion proteins constructed
with the most active double epitope mutants when conﬁgured with a
furin linker, re-formatted with the G4S linker revealed that these
constructs had almost the same activity as WT α-sarcin in the same
conﬁguration. Thus, the presence of a G4S linker appears to have
enhanced the activity of the scFv-deimmunised variant fusions.
These results suggest that WT and deimmunised variant α-sarcins
are able to either separate from the anti-Her2 scFv in the endosomes
and effectively penetrate the cell cytoplasm without requirement for
a protease cleavage site or, alternatively, it is possible that the whole
fusion protein with the G4S linker translocates to the cytoplasm and
the presence of the anti-Her2 scFv does not affect ribosome binding
and cytotoxicity. Similarly, other studies using a scFv to GPA33
fused with WT α-sarcin containing a G4S linker effectively killed
cells and demonstrated anti-tumour effects in vivo (Carreras-Sangrà
et al., 2012; Tomé-Amat et al., 2015a). It is possible that different
targeting moieties (scFvs) to the same target or to different targets
will trafﬁc and process differently when fused with the new deimmu-
nised α-sarcin variants. Therefore, optimisation of the linker may
further improve the potency of these α-sarcin immunotoxins.
Based upon the collective results, deimmunised α-sarcin variants
D9T/Q142T and P13I/Q142T were selected as lead candidates and
tested in the whole protein ex vivo DC:T cell assay. WT α-sarcin
was included as a control and elicited responses in 20% of the
donor cohort. This suggests that α-sarcin itself has a relatively low
inherent potential for immunogenicity compared to other bacterially
derived immunotoxins (e.g. PE38). Moreover, this observation is
consistent with the data from T cell epitope mapping, which indi-
cated that the two T cell epitopes identiﬁed in the α-sarcin sequence
were of relatively low potency, and with previous studies showing
that the related fungal ribotoxin, restrictocin, was poorly immuno-
genic in immunised mice (Rathore and Batra, 1996). Deimmunised
variant P13I/Q142T induced positive T cell responses in 10% of the
donor cohort, while deimmunised variant D9T/Q142T failed to
induce any responses. While the ex vivo T cell assays are not pre-
dictive of immunogenicity in vivo, we have previously shown a good
correlation between these assays and clinical experience (Baker and
Jones, 2007) in particular, therapeutics that have been demonstrated
to be associated with low rates of ADA in the clinic give low fre-
quencies of responses in the T cell assay; although certainty can only
be demonstrated by clinical testing. Notwithstanding this caveat,
variant D9T/Q142T, preferentially conﬁgured without the His tag,
could be linked to any cancer-targeting binding domain to create
immunotoxins with the potential for reduced risk of eliciting
treatment-limiting ADA.
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Supplementary data are available at PEDS online.
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